Treatment of hepatitis C before and after liver transplantation;Tratamiento de la hepatitis C antes y después del trasplante hepático

Gastroenterologia y Hepatologia

Volumn 29, Issue SUPPL. 2, 2006, Pages 190-195

  Berenguer, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LIVER CIRRHOSIS; LIVER SURGERY; LIVER TRANSPLANTATION; MONOTHERAPY; PROGNOSIS; PROPHYLAXIS; RECURRENT DISEASE; SURGICAL TECHNIQUE; VIRUS INFECTION;

EID: 34547877273     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13097658     Document Type: Conference Paper

References (49)

1. García-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver trasplantation. Hepatology. 2002;35:680-7.
2. Berenguer M. Hepatitis C and liver trasplantation. Curr Op Organ Transpl. 2005;10:81-9.
3. Wiesner RH, Sorrell M, Villamil F. Report of the First International Liver Trasplant Society Consensus Conference on Liver Trasplantation and Hepatitis C. Liver Transpl. 2003;9(Suppl 3):S1-9.
4. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver trasplantation. Hepatology. 2000;32:852-8.
5. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver trasplantation. Gastroenterology. 2002;122: 889-96.
6. Berenguer M, Prieto M, San Juan F, Rayón M, Martínez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver trasplant recipients. Hepatology. 2002;36:202-10.
7. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver trasplants for chronic hepatitis C: a 10-year follow-up. Trasplantation. 2004;77:226-31.
8. Bizollon T, Admed SNS, Radenne S, Chevallier M, Chevallier P, Paraz P, et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver trasplant patients with hepatitis C recurrence. Gut. 2003;52: 283-7.
9. Abdelmalek MF, Firpi RJ, Soldevila-Picó C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver trasplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10:199-207.
10. Berenguer M. Treatment of hepatitis C after liver trasplantation. Clin Liv Dis. 2005;9(4):579-600.
11. Crippin JS, Sheiner P, Terrault NA, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver trasplantation for hepatitis C. Liver Transpl. 2002;8:350-5.
12. Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver trasplantation. J Hepatol. 2003;39:389-96.
13. Thomas RM, Brenns JJ, Guzmán-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver trasplantation: a role for interferon therapy before trasplantation. Liver Transpl. 2003;9:905-15.
14. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42: 255-62.
15. Willems B, Ede M, Marotta P, Wall W, Greig P, Lilly L, et al. Anti-HCV human immunoglobulin for the prevention of graft infection in HCV-related liver trasplantation-A pilot study [resumen]. J Hepatol. 2002;36:32.
16. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al; Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver trasplant recipients. Liver Transpl. 2005;11(8):941-9.
17. Sheiner P, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver trasplantation. Hepatology. 1998;28:831-38.
18. Singh N, Gayowski T, Wannstedt C, Shakil O, Wagener M, Fung J, et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver trasplant recipients. Trasplantation. 1998;65: 82-6.
19. Mazzaferro V, Tagger A, Schiavo M, Regalia A, Pulvirenti M, Ribero J, et al. Prevention of recurrent hepatitis C after liver trasplantation with early interferon and ribavirin treatment. Transpl Proc. 2001;33:1355-7.
20. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana R, Reily C, et al. Peginterferon alfa 2a for recurrence of hepatitis C after liver trasplantation: two randomised, controlled trials. Hepatology. 2005;41(2):289-98.
21. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher N, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver trasplantation. Am J Transpl. 2005;5:118-24.
22. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, et al. Preemptive therapy for hepatitis C virus after living-donor liver trasplantation. Trasplantation 2004;78(9):1308-11.
23. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver trasplantation. Hepatology. 1997:26:500-4.
24. Alberti AB, Belli LS, Airoldi A, De Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttrasplantation recurrent hepatitis C: a pragmatic study. Liver Transpl. 2001;7:870-6.
25. Firpi RJ, Abdelmalek MF, Soldevila-Picó C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver trasplant recipients with histological recurrent hepatitis C. Liver Transpl. 2002;8:1000-6.
26. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver trasplantation with combination interferon plus ribavirin. Liver Transpl. 2001;7:181-90.
27. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver trasplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl. 2001;7:863-9.
28. Kornberg A, Hommann M, Tannapfel A, Wagner T, Grube T, Schotte U, et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver trasplant patients. Am J Transpl. 2001;1:350-5.
29. De Vera ME, Smallwood GA, Rosado K, Davis L, Martínez E, Sharma S, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver trasplantation. Trasplantation. 2001;71:678-86.
30. Narayanan M, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, et al. Treatment of posttrasplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002;8:623-9.
31. Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Treatment of recurrent hepatitis C in liver trasplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol. 2002;37:247-52.
32. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, et al. A pilot study of interferon alfa and ribavirin combination in liver trasplant recipients with recurrent hepatitis C. Hepatology. 2002;36:1253-8.
33. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver trasplantation: a randomized study. Gastroenterology. 2003;124:642-50.
34. Giostra E, Kullak-Ublick GA, Keller W, Fried R, Vanlemmens C, Kraehenbuhl S, et al. Ribavirin/interferon-alfa sequential treatment of recurrent hepatitis C after liver trasplantation. Transpl Int. 2004;17:169-76.
35. Berenguer M, Prieto M, Palau A, et al Recurrent hepatitis C genotype 1b following liver trasplantation (OLT): treatment with combination interferon-ribavirin therapy (CT). Eur J Gastro Hepatol. 2004;16(11):1207-12.
36. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. Pegylated interferon for recurrent hepatitis C in liver trasplant recipients with renal failure: a prospective cohort study. Transpl Proc. 2003;35:1478-9.
37. Ross AS, Bhan AK, Pascual M, Thiim M, Cosimi AB, Chung RT. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver trasplant recurrent hepatitis C. Clin Trasplant. 2004;18:166-73.
38. Dumortier J, Scoaxec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver trasplantation: a pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol. 2004;40:669-74.
39. Rodríguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver trasplantation with combination of pegylated interferon alfa 2b and ribavirin: an open label series. Trasplantation. 2004;77:190-4.
40. Neff GW, Montalbano M, O'Brien C, Nishida S, Dafdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver trasplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transpl. 2004;78:303-7.
41. Berenguer M, Palau A, Fernández A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver trasplant recipients with recurrent hepatitis C. Liver Transpl. 2006;12:1067-76.
42. Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E, Bonvicini F, et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver trasplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis. 2006;38(1):27-32.
43. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver trasplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol. 2005;19(6):359-65.
44. Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-trasplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol. 2005;20(4):577-82.
45. Todd-Stravitz R, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver trasplantation. Liver Transpl. 2004;10:850-8.
46. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver trasplant recipients. Liver Transpl. 2004;10:859-67.
47. Regev A, Molina E, Moura R, Bejarano PA, Khaled A, Ruiz P, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver trasplantation. Liver Transpl. 2004;10:1233-9.
48. Bizollon T, Adham M, Pradat P, Chevallier M, Ducerf C, Baulieux J, et al. Triple antiviral therapy with amantadine for IFNribavirin nonresponders with recurrent posttrasplantation hepatitis C. Trasplantation. 2005;79:325-9.
49. Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver trasplantation. J Hepatol. 2005;43(1):53-9.